SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017)
SELLAS Life Sciences (SLS) reported Return on Invested Capital of 0.01% for Q4 2017, down 525.11% quarter-over-quarter from 0.0% in Q3 2017.
SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 3 years of Return on Invested Capital data on file, last reported at 0.01% in Q4 2017.
- Return on Invested Capital for Q4 2017 came in at 0.01%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was 0.01% (changed N/A YoY), and the FY2021 annual result was 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital slipped to 0.01% in Q4 2017 per SLS's latest filing, from 0.0% in the prior quarter.
- Over five years, Return on Invested Capital peaked at 0.0% in Q3 2017 and troughed at 0.01% in Q3 2014.
- A 3-year average of 0.01% and a median of 0.01% in 2014 frame the typical range for Return on Invested Capital.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.01% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -0.01% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -0.01% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -0.01% |
| Sep 30, 2017 | 0.00% |
| Jun 30, 2017 | 0.00% |
| Sep 30, 2014 | -0.01% |
| Jun 30, 2014 | -0.01% |
| Mar 31, 2014 | -0.01% |
| Dec 31, 2013 | -0.01% |